Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis

J Neurol. 2014 May;261(5):1021-4. doi: 10.1007/s00415-014-7311-1. Epub 2014 Mar 18.

Authors

Muriel Stoppe¹, Eva Thomä, Uwe Gerd Liebert, Eugene O Major, Karl-Titus Hoffmann, Joseph Claßen, Florian Then Bergh

Affiliation

¹ Department of Neurology, University of Leipzig, Liebigstraße 20, 04103, Leipzig, Germany.

PMID: 24638202
DOI: 10.1007/s00415-014-7311-1

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Cerebellum / drug effects*
Cerebellum / pathology
Cerebellum / virology
Dimethyl Fumarate
Fumarates / adverse effects*
Humans
Leukoencephalopathy, Progressive Multifocal / chemically induced*
Leukoencephalopathy, Progressive Multifocal / diagnosis
Leukoencephalopathy, Progressive Multifocal / drug therapy*
Male
Psoriasis / diagnosis
Psoriasis / drug therapy*
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Fumarates
Dimethyl Fumarate
efalizumab